Sapience Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Team
    • Directors
    • Advisors
  • Our Approach
    • Overview
    • Therapeutic Approach
    • Discovery Platform
  • Pipeline
    • Overview
    • ST101
    • β-Catenin Antagonist
    • cJun Antagonist
    • cMyc Antagonist
    • FoxP3 Antagonist
  • Partnering
  • Careers
  • News & Events
    • Press Releases
    • Events
    • Publications
    • Presentations
    • Email Alerts
  • Contact

Press Releases

News & Events

News & Events

  • Press Releases
  • Events
  • Publications
  • Presentations
  • Email Alerts
May 10, 2017 9:36am EDT

Sapience Therapeutics Adds Biotech Veteran, Christian S. Schade, to Board of Directors

Mar 29, 2017 9:36am EDT

Sapience Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ST-36 for the Treatment of Glioma

Sep 07, 2016 9:36am EDT

Sapience Therapeutics Adds Former Head of the National Cancer Institute, Samuel Broder, MD, to Board of Directors

Jul 20, 2016 9:36am EDT

Sapience Therapeutics, Inc. Enters Into Exclusive License Agreement With Columbia University for Novel Cancer Treatment

Jul 12, 2016 9:36am EDT

Sapience Therapeutics Completes $22.5 Million Series A Financing

  • Previous
  • 1
  • 2
  • 3
RSS
© 2021 Sapience Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap